Ranked #3,348 of 8,699 institutional investors
Spruce Street Capital LP
New York, NY
$570M
US stock portfolio at live prices · today −$16.9M (−2.88%)
Live prices, last trade 12:11 PM ET
- Value at quarter end (Q3 2026)
- $629M
- Change from Q2 2026
- +$119.3M (+23.41%)
- Positions
- 29 · 5 new, 0 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$174M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesLBRX 9.54%RLAY 8.36%ANRO 7.39%DNTH 5.25%SVRA 4.05%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LBRX LB Pharmaceuticals Inc | 1,404,779 | $54.4M | 9.54% | Added +2% |
| RLAY Relay Therapeutics, Inc. | 2,984,125 | $47.7M | 8.36% | Unchanged |
| ANRO Alto Neuroscience Inc | 1,676,558 | $42.2M | 7.39% | Added +24% |
| DNTH Dianthus Therapeutics, Inc. | 354,816 | $30.0M | 5.25% | Unchanged |
| SVRA Savara Inc. | 5,381,941 | $23.1M | 4.05% | Added +56% |
| ZLAB Zai Lab Limited | 1,042,158 | $21.5M | 3.78% | Added +273% |
| RLMD Relmada Therapeutics, Inc. | 6,912,191 | $19.3M | 3.39% | Added +8% |
| PCVX Vaxcyte, Inc. | 306,047 | $17.3M | 3.03% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 329,006 | $15.1M | 2.65% | Unchanged |
| OBX Obsidian Therapeutics, Inc. | 1,249,943 | $15.0M | 2.63% | New |
| SRZN Surrozen, Inc. | 432,040 | $12.7M | 2.22% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 1,400,000 | $12.6M | 2.22% | New |
| KRSA Korsana Biosciences, Inc. | 338,951 | $12.5M | 2.19% | New |
| ANTX AN2 Therapeutics, Inc. | 1,752,011 | $8.9M | 1.56% | Added +5% |
| ENTA Enanta Pharmaceuticals, Inc. | 1,088,731 | $8.3M | 1.46% | Unchanged |
| YARW Yarrow Bioscience, Inc. | 607,382 | $8.1M | 1.41% | New |
| SABS SAB Biotherapeutics, Inc. | 2,198,502 | $6.0M | 1.06% | Unchanged |
| ERAS Erasca, Inc. | 422,543 | $5.9M | 1.04% | Unchanged |
| ALEC Alector, Inc. | 2,101,068 | $4.9M | 0.87% | Unchanged |
| IPSC Century Therapeutics, Inc. | 4,059,054 | $4.8M | 0.85% | Unchanged |
| IKT Inhibikase Therapeutics, Inc. | 3,581,603 | $4.6M | 0.81% | Unchanged |
| QUIT Achieve Life Sciences, Inc. | 736,637 | $4.2M | 0.73% | Unchanged |
| NERV Minerva Neurosciences, Inc. | 1,655,500 | $3.4M | 0.60% | Unchanged |
| ATTO Attovia Therapeutics, Inc. | 228,295 | $3.4M | 0.59% | New |
| LXEO Lexeo Therapeutics, Inc. | 928,593 | $2.9M | 0.51% | Unchanged |
| CATX Perspective Therapeutics, Inc. | 3,693,931 | $2.8M | 0.50% | Unchanged |
| CRVS Corvus Pharmaceuticals, Inc. | 231,585 | $2.2M | 0.39% | Unchanged |
| ALMS Alumis Inc. | 392,574 | $1.6M | 0.28% | Unchanged |
| LONA LeonaBio, Inc. | 393,701 | $907K | 0.16% | Unchanged |